Risk Warning The value of investments can fall as well as rise and any income from them is not guaranteed and you may get back less than you invested. Past performance is not a guide to future performance.

Share Price:
Up 184.65p
Change Today:
0.85p
Market Cap:
130.41m
Sector:
Medical Equipment and Services

Novacyt gets UK approval for 'genesig' Covid-19 test

By Josh White

Date: Friday 26 Nov 2021

LONDON (ShareCast) - (Sharecast News) - Clinical diagnostics specialist Novacyt announced on Friday thatots 'genesig' Covid-19 real-time PCR test has been approved in the UK.
The AIM-traded firm said it was its first test to be added to the Coronavirus Test Device Approvals (CTDA) register, with it now preparing to resume the sale of the product in the UK.

It launched the 'genesig' assay on 31 January 2020 as one of the world's first commercially-available tests for Covid-19.

To date, the test, which targets the ORF1ab gene, was still able to detect all known variants and mutations of the coronavirus, with more than 4.5 million sequences analysed.

As it announced on 2 November, the company had submitted 11 products for review under the CTDA to meet the original submission deadline of 1 September.

Further to the validation of its genesig test, Novacyt's 'Primerdesign PROmate' Covid-19 test remained on the temporary protocol, and was still being supplied to the NHS under the PHE National Microbiology Framework.

The company said it was awaiting updates on the eight further products submitted to the CTDA across its Covid-19 testing portfolio.

Novacyt noted that only validated products, or products on the temporary protocol, could be sold in the UK after 31 October.

On 2 November, Novacyt also said that if no further products were added to the CTDA register, the impact on full-year revenues for 2021 would be around 3m.

With the new approval on Friday, the company said the financial impact on 2021 would be "significantly lower" as the genesig test accounted for about 30% of the 3m revenue shortfall.

"I am delighted to announce that our genesig Covid-19 test has become the seventh product to be approved and added to the CTDA register," said group chief executive officer David Allmond.

"With the associated resumption of the sale of this product in the UK, we look forward to ensuring our customers continue to have access to this market leading test during the winter season."

Allmond said the genesig test was launched in late January 2020, and was recognised globally by leading public health bodies, including the US Food and Drug Administration (FDA), alongside long-term agreements with both UNICEF and the World Health Organization.

"We continue to engage with the UK Health Security Agency and look forward to further updates on our tests still under review."

At 0945 GMT, shares in Novacyt were up 12.47% at 373.4p.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

NCYT Market Data

Currency UK Pounds
Price 184.65p
Change Today 0.85p
52 Week High 1,158.00p
52 Week Low 171.33p
Volume 1,313,723
Shares Issued 70.63m
Market Cap 130.41m
Beta 0.10

Performance Indicators

Compare performance with the sector and the market.

Key
Vs Market
Vs Sector
Value
market
  1. full market star
  2. full market star
  3. full market star
  4. full market star
  5. half market star
sector
  1. full sector star
  2. full sector star
  3. full sector star
  4. full sector star
  5. full sector star
Price Trend
market
  1. full market star
  2. half market star
  3. empty market
  4. empty market
  5. empty market
sector
  1. full sector star
  2. half sector star
  3. empty sector
  4. empty sector
  5. empty sector
Income
Not Available
Growth
market
  1. full market star
  2. full market star
  3. full market star
  4. full market star
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. full sector star
  4. full sector star
  5. half sector star
Price Chg 6m
market
  1. half market star
  2. empty market
  3. empty market
  4. empty market
  5. empty market
sector
  1. full sector star
  2. empty sector
  3. empty sector
  4. empty sector
  5. empty sector
P/E
market
  1. full market star
  2. full market star
  3. full market star
  4. full market star
  5. full market star
sector
  1. full sector star
  2. full sector star
  3. full sector star
  4. full sector star
  5. full sector star
PEG
market
  1. full market star
  2. full market star
  3. full market star
  4. half market star
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. half sector star
  4. empty sector
  5. empty sector
Dividend Yield
Not Available
EPS Growth
Not Available
Operating Margin
market
  1. full market star
  2. full market star
  3. full market star
  4. full market star
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. full sector star
  4. full sector star
  5. full sector star

NCYT Dividends

No dividends found

Trades for 26-Jan-2022

Time Volume / Share Price
14:53 500 @ 184.65p
14:52 500 @ 183.65p
14:51 850 @ 181.35p
14:51 449 @ 184.70p
14:51 500 @ 181.35p

NCYT Key Personnel

CFO James McCarthy
CEO David Allmond